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Abstract
The move toward universal provision of antiretroviral therapy and the expansion of HIV viral load monitoring call into question
the ongoing value of CD4 cell count testing and monitoring. We highlight the role CD4 monitoring continues to have in guiding
clinical decisions and measuring and evaluating the epidemiology of HIV. To end the HIV/AIDS epidemic, we require strategic
information, which includes CD4 cell counts, to make informed clinical decisions and effectively monitor key surveillance
indicators.
(JMIR Public Health Surveill 2019;5(1):e11136)   doi:10.2196/11136
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The CD4 cell count has been the principal basis for assessing
an HIV-infected person’s level of immunosuppression and for
timing initiation of antiretroviral therapy (ART) [1]. In 2015,
the World Health Organization (WHO) recommended starting
ART at any CD4 count, regardless of the clinical symptoms or
conditions [2]. These guidelines and subsequent studies argue
that, for clinical purposes, the frequency of CD4 monitoring
post-ART initiation can be reduced or ceased when viral load
testing is available and patients are suppressed [2-6].
The move toward universal ART, the expansion of viral load
monitoring [7-9], and recommendations to reduce or cease CD4
testing post-ART initiation call into question the value of CD4
testing. Decreased support for CD4 testing could potentially
not only result in reduced CD4 monitoring among people who
have initiated ART, but also unintentionally lead to reduced
quality of monitoring at diagnosis and the period up to ART
initiation. In this communication, we highlight the continuing
role of CD4 monitoring in guiding clinical decisions and
measuring and evaluating the epidemiology of HIV.
The routine collection of CD4 data at diagnosis (baseline) from
laboratories and health care facilities (conducting primary or
confirmatory HIV tests) continues to provide an assessment of
treatment priorities. Importantly, this information remains
critical in identifying late diagnosis (as often indicated by a CD4
count of <350 cells/µL) [10-12]. A late diagnosis indicates that
a person is at a significantly elevated risk of HIV-related
opportunistic infections and mortality, and has been identified
as a primary cause of HIV-related deaths in settings where ART
is widely and freely available [10,12-13].
Low CD4 counts are triggers for more intensive follow-up and
care in differentiated care models. For example, WHO guidelines
on advanced disease recommend that people with a CD4 count
<100 cells/µL be screened for cryptococcal disease and managed
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with fluconazole if asymptomatic, those with a CD4 <200
cells/µL receive tailored counselling, and those with a CD4
<350 cells/µL receive cotrimoxazole prophylaxis [14]. It is also
recommended that people living with HIV with a count <100
cells/µL be offered the urinary lipoarabinomannan point-of-care
test for tuberculosis [14]. In this way, CD4 is facilitating a shift
away from symptom-based tuberculosis screening toward an
approach of testing all those at high risk of disease. In Uganda,
ART-naïve adults with CD4 counts ≤250 cells/µL are currently
screened for tuberculosis and those with CD4 ≤100 cells/µL are
also screened for cryptococcal antigen [15], similar to the case
in South Africa [16]. In a recent three-country trial, presumptive
antimicrobial treatment in patients initiating ART with CD4
counts <100 cells/µL resulted in a 30% reduction in 6-month
mortality [17]. The routine collection and use of CD4 data have
also been shown to be cost effective in promoting clinical
outcomes such as disability-adjusted life years averted [18,19].
As loss to follow-up is a common outcome along the HIV care
continuum [20], it is important that differentiated care models,
informed by CD4 monitoring, also consider persons re-engaging
in care.
Clinically mediated CD4 monitoring has also been an important
feature of HIV surveillance. At the population level, the
prevalence of CD4-defined late diagnoses helps monitor the
effectiveness of program efforts for early identification [11,21]
and is a WHO linkage to care indicator [21]. The linkage of
CD4 data at diagnosis with longitudinal CD4 cell counts up to
ART initiation has provided important information on
trajectories of CD4 depletion between diagnosis and treatment.
This information has been used at international, national, and
subnational levels to back calculate from the time of diagnosis
to the probable time of infection in order to estimate the
incidence of HIV [22-26], estimate the prevalence of
undiagnosed HIV [24-28], and assign a probable place of
infection [29,30].
In a number of settings, the application of CD4-based models
and their analyses are either being expanded or newly adopted.
In 2016, a new model incorporating CD4 at or after diagnosis,
but before ART, was introduced in the United States to estimate
HIV incidence, prevalence, and undiagnosed infections [24].
Among European Union member states, a CD4 back-calculation
model, which assigns probable place of HIV infection among
migrant populations by estimating the time of infection and
comparing it with the time of arrival in the host country, is being
promoted to inform prevention programs [29,30]. In addition
to informing pre-ART care and policy decisions concerning the
use of ART for prevention [31], routine CD4 monitoring in
South Africa has recently been used to assess the risk of
subsequent loss to follow-up from care [32] and to estimate care
cascade measures [33]. Although most of the CD4-based
activities cited are focused in middle- and high-income settings,
the promotion of HIV case surveillance [34] and the collection
of CD4 within these systems will hopefully further expand the
application of these methods to low- and middle-income settings,
including high-prevalence settings in sub-Saharan Africa.
Clinical and surveillance activities relying on CD4 testing will
be impaired if testing is reduced or discontinued between
diagnosis and ART initiation, or in a setting where viral load
testing remains suboptimal. Although it has been suggested that
access to viral load monitoring in low-income, high-HIV burden
settings may be limited [4], the Joint United Nations Programme
on HIV/AIDS in 2016 reported that a number of resource-limited
countries have drastically reduced CD4 monitoring in favor of
increased viral load testing [35]. In 2018, the President’s
Emergency Plan for AIDS Relief announced that they will
reduce their overall level of support in donor countries for CD4
testing to prioritize viral load testing [36].
Although CD4 monitoring remains essential for the detection
and management of HIV-related opportunistic infections such
as Cryptococcus, signatories of a 2017 advanced HIV position
statement claim donor support for CD4 testing at the primary
care level has decreased in recent years [37]. The signatories of
this statement included Médecins Sans Frontières. Figure 1
presents ART initiation by CD4 count in a Médecins Sans
Frontières treatment program in South Africa. The top bar of
the figure suggests an increase in recent years in the number
and proportion of people not receiving a CD4 test at the time
of treatment initiation. The reduction of CD4 monitoring both
at and subsequent to diagnosis has also been brought to the
attention of a research team carrying out HIV system
assessments in resource-limited settings in 2015 and 2016 (R.
Harklerode, personal communication, January 2018) [38].
While highlighting the role of continuing CD4 monitoring in
informing clinical and epidemiological activities, we remain
fully supportive of the expansion of viral load monitoring. In
several areas of clinical management, for example, the
monitoring of pediatric HIV infection [39], a combination of
CD4 and viral load monitoring is essential. As CD4 tests are
more affordable than viral load tests in many countries [18,19]
and have already been scaled up, we believe CD4 monitoring
presents a model of learning for scaling up optimal and
affordable viral load testing.
It is inevitable that the role of CD4 monitoring in guiding
clinical decisions will become more selective. However,
vigilance and oversight are required to ensure that while we
reduce reliance on CD4 monitoring in virologically suppressed
patients, we retain our capacity to conduct CD4 testing at
diagnosis and up to ART initiation. This remains critically
important in diagnosing and treating comorbidities, determining
whether a person requires an advanced package of screening
and care, reducing mortality, and ensuing the continuity of
critical data for surveillance activities (such as estimating HIV
incidence and undiagnosed infections). Although we do not
advocate for routine CD4 monitoring for all, CD4 should
continue to guide the clinical management of persons
re-engaging in care or remaining in care but failing treatment.
Capacity will preferably be retained at the population level;
where this is not the case, representative sampling methods
should be considered. To end the HIV/AIDS epidemic, we must
obtain essential data to make informed clinical decisions and
effectively monitor key surveillance indicators.
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Figure 1. ART initiations in Eshowe and Mbongolwane, KwaZulu-Natal, stratified by CD4 count, 2011 to 2017. CD4 counts are measured as CD4
cells/µL. Q1 was from January to end March 2017. ART: antiretroviral therapy.
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